COMPARISON OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TESTED AND NOT-TESTED METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) PATIENT COHORTS IN EUROPE
Author(s)
Narayanan S1, Gallo F2
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA
Presentation Documents
OBJECTIVES: Compare the characteristics of mNSCLC patients either tested or not for Human Epidermal Growth Factor Receptor 2 mutation (EGFRm/HER2) in Europe. METHODS: A multi-country retrospective medical chart-review of mNSCLC patients were conducted by cancer treating physicians in Germany/France/Spain/Italy (EU4) and the UK; Data collection period was Jan-Dec 2013. Physicians were recruited from a geographically representative sample in each country. Approximately 10-25 eligible patients on usual care anti-cancer regimen were identified by each physician within the four-quarterly study observation-window. Physicians abstracted data on patient demographics, disease status, treatment patterns and biomarker status .The analysis focused on patients that were either tested (T) or not-tested (NT) for EGFRm in UK & EU4. RESULTS: Approximately 4800 mNSCLC patient-charts (UK~630/4EU~4170) were collected in 2013. 62%/62% were tested for EGFRm in the UK/4EU respectively. Mean age was: T-64yrs/NT-67yrs in both UK and EU4; proportion of patients who were male: T-56%/NT-64% in UK, T-61%/NT-78% in EU4. Proportion of patients who ‘never smoked’ was: T-29%/NT-9% in UK, T-23%/NT-12% in EU4. Time since disease diagnosis was: T-6mo/NT-10mo in UK, T-9mo/NT-9mo in EU4. Proportion of patients newly diagnosed: T-53%/NT-38% in UK, T-39%/NT-50% in EU4; % in relapse: T-24%/NT-50% in UK, T-32%/NT-19% in EU4. Proportion of patients with an ECOG score of >=2 at the time of visit: T-4%/NT-12% in UK, T-24%/NT-24% in EU4. CONCLUSIONS: Distinct differences appear to exist within mNSCLC cohorts based on the EGFRm test status (T/NT) and geography (UK/EU4). This warrants further research to understand the drivers behind the observed patterns (including the dynamics of respective national healthcare systems, access to biomarker testing, and physicians’ perception of patient suitability for EGFRm testing) and to facilitate optimal care delivery that could eventually lead to the utilization of targeted oncology therapeutics to alleviate patient burden and improve outcomes.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PMD118
Topic
Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Pricing Policy & Schemes, Treatment Patterns and Guidelines
Disease
Oncology